A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A randomized-control, double-blind, multi-center, delayed-start, pilot trial evaluating the
disease modifying effects of a 150mg once-a-day dose vs. placebo of dabigatran in men and
women, between the ages of 50-85 years, confirmed with MCI probably due to AD and mild
Alzheimer's Disease.
Phase:
Phase 1
Details
Lead Sponsor:
University of Rhode Island
Collaborators:
Alzheimer's Drug Discovery Foundation Alzheimer’s Drug Discovery Foundation Boehringer Ingelheim